Review article: Angiogenesis soluble factors as liver disease markers

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 1, 2005, Pages 23-30

  Salcedo, X ^a   Medina, J ^a   Sanz Cameno, P ^a   Garcia Buey L ^a   Martin Vilchez S ^a   Moreno Otero, R ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; ENDOGLIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MATRIX METALLOPROTEINASE; PLACENTAL GROWTH FACTOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCATTER FACTOR; TIE 1 RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CANCER INVASION; CANCER STAGING; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; DISEASE COURSE; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER DISEASE; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH; VIRUS HEPATITIS;

ANGIOGENESIS INDUCING AGENTS; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 21744460505     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02532.x     Document Type: Review

References (63)

1. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-95.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
3. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
4. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N Eng J Med 1991; 324: 1-8.
5. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3: 643-51.
6. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
7. Schimming R, Reusch P, Kuschnierz J, Schmelzeisen R. Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Craniomaxillofac Surg 2004; 32: 176-81.
8. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G. Tumour specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003; 82: 147-54.
9. Coskun U, Gunel N, Sanck B. Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients. Breast Cancer Res Treat 2003; 12: 104-10.
10. Kinouchi T, Mano M, Matsuoka I, et al. Immature tumour angiogenesis in high-grade and high-stage renal cell carcinoma. Urology 2003; 62: 765-70.
11. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-80.
12. Chong AY, Caine GJ, Lip GY. Angiopoietin/Tie-2 as mediators of angiogenesis: a role in congestive heart failure? Eur J Clin Invest 2004; 34: 9-13.
13. Medina J, Sanz-Cameno P, García-Buey L, Martín- Vílchez S, López-Cabrera M, Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol 2005; 42: 124-31.
14. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004; 34: 1660-4.
15. Tannock IF. The relation between cell proliferation and the vascular system in transplanted mouse mammary tumour. Br J Cancer 1968; 22: 258-73.
16. Lai WK, Adams DH. Angiogenesis and chronic inflammation: the potential for novel therapeutic approaches in chronic liver disease. J Hepatol 2005; 42: 7-11.
17. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
18. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
19. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 2004; 183: 713-9.
20. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713-25.
21. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy; rationale, challenges and clinical studies. Angiogenesis 2002; 5: 237-56.
22. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
23. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32A: 2413-22.
24. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211-20.
25. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617-23.
26. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-54.
27. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998; 95: 11709-14.
28. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28: 488-94.
29. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 393-402.
30. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992-7.
31. Sekiya M, Ohwada A, Miura K, Takahashi S, Fukuchi Y. Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 2003; 181: 259-65.
32. Guedj N, Couvelard A, Arcangeli G, et al. Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours. Histopathology 2004; 44: 251-6.
33. Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 504-8.
34. Srivastava M, Zurakowski D, Cheifetz P, Leichtner A, Bousvaros A. Elevated serum hepatocyte growth factor in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 548-53.
35. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-83.
36. Hirashima M, Lu Y, Byers L, Rossant J. Trophoblast expression of fms-like tyrosine kinase 1 is not required for the establishment of the maternal-fetal interface in the mouse placenta. Proc Natl Acad Sci U S A 2003; 100: 15637-42.
37. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004; 95: 884-9.
38. Holland CM, Day K, Evans A, Smith SK. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003; 89: 891-8.
39. Mazurek A, Pierzynski P, Kuc P, et al. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer. Neoplasma 2004; 51: 193-7.
40. Theodoridou S, Vyzantiadis T, Vakalopoulou S, et al. Elevated levels of serum vascular endothelial growth factor in patients with polycythaemia vera. Acta Haematol 2003; 110: 16-9.
41. Cirulli A, Liso A, D'Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110: 29-32.
42. Homer JJ, Greenman J, Drevs J, Marme D, Stafford ND. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma. Head Neck 2002; 24: 773-8.
43. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. Quantitative correlation of serum levels and tumour expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003; 63: 3121-6.
44. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
45. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273: 83-101.
46. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
47. Park YN, Kim Y, Yang K, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-5.
48. Jinno K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumour marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33: 376-82.
49. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233: 227-35.
50. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355-62.
51. Poon RT, Ho J, Tong C, Lau C, Ng I, Fan S. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91: 1354-60.
52. Poon RT, Lau C, Yu W, Fan S, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11: 1077-84.
53. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Oncol Int J 1999; 14: 1087-90.
54. Hisai H, Kato J, Kobune M, et al. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumour vascularity. Clin Cancer Res 2003; 9: 4852-9.
55. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40: 252-9.
56. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999; 103: 341-5.
57. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-13.
58. Tanaka S, Sugimachi K, Yamashita Yi Y, et al. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology 2002; 35: 861-7.
59. García-Monzon C, Sánchez-Madrid F, García-Buey L, García-Arroyo A, García-Sánchez A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-41.
60. Mazzanti R, Messerini L, Monsacchi L, et al. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997; 25: 229-34.
61. Shimoda K, Mori M, Shibuta K, Banner BF, Barnard GF. Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int J Oncol 1999; 14: 353-9.
62. Medina J, Caveda L, Sanz-Cameno P, et al. Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J Hepatol 2003; 38: 660-7.
63. Salcedo-Mora X, Sanz-Camero P, Martín-Vílchez S, et al. Proangiogenic factors are increased in serum of patients with chronic hepatitis c and correlate with markers of disease progressions (abstract). Hepatology 2004; 40: 721A.